NeoNotes Journal Club Index
FSN Home Page | List of Articles | Search | Email the Editor

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z #

Select the first letter of the topic from the list above to jump to appropriate section of the index.

- A -

Acoustic output and deadspace determination: 1-013

Acuity adjustment scores: 3-010

Albuterol treatment for hyperkalemia: 1-034

Alcohol, on umbilical cords: 4-001 ; 5-010

Aldactone treatment for CLD: 1-015

Alloimmune thrombocytopenia: 8-037

Aluminum toxicity: 10-045

Amniocentesis, complications: 3-007

Amnioinfusion: 6-031

Amniopatch for premature rupture of membranes: 3-007

Anemia:

Complications: 2-038

Evaluation of: 2-041 ; 2-042 ; 2-043; 2-044; 2-045

Prevention: 1-024; 1-028; 3-015 ; 3-019 ; 3-037 ; 4-040 ; 6-004; 7-005

Antenatal steroids: 2-006 ; 2-051 ; 3-014

Antibiotic treatment:

and 48-hour cultures: 3-042 ; 6-014 ; 7-002
and Necrotizing enterocolitis: 10-011
for neonatal pneumonia: 1-029
with premature rupture of membranes: 3-006

Anticonvulsants and birth defects: 1-038

Apgar Scores: 1-003; 10-048

Apnea :

After Immunizations: 8-032 ; 9-036
and GE reflux: 3-001 ; 3-012 ; 6-041; 10-015
and sedation: 3-013
and supine positioning : 1-016
aroma therapy for: 6-002
evaluation: 3-001 ; 3-002 ; 3-012 ; 4-042
nasal canula vs CPAP: 2-022
of Prematurity: 7-034 ; 7-035; 8-017; 8-048
Treatment : 7-034 ; 7-035; 8-017 ; 8-048

Aquaphor lotion: 1-041

Arginine supplementation: 3-027

Arterial catherers, complications: 3-038

Atelectasis, treatment: 2-032

- B -

B-type natriuretic peptide (BNP): 11-009

Baby CareLink: 1-039

Bereavement: 10-033

Betamethasone: 7-018

Biliary atresia, diagnosis: 2-031

Bilirubin: 3-031 ; 4-023 ; 5-023 ; 5-024; 7-007; 7-017; 10-022

Birth defects:

and folic acid antagonists: 1-038

bleeding

time: 2-038
Treatment: 7-043

Blood cultures: 3-042

Blood Drawing: 3-016

Blood Pressure: 5-039\ 10-032

Blood transfusions:

and bleeding time: 2-038
and NEC: 11-024
delayed cord clamping and : 1-024 ; 3-019; 9-017
erythropoietin and : 3-015 ; 3-037
feeding during: 11-024
Iron supplementation and: 1-028

brachial plexus palsies, surgery for: 1-022

Bradycardia:

and GE reflux: 3-001 ; 3-012; 10-037
and sedation: 3-013
and supine positioning: 1-016
evaluation: 3-001 ; 3-002 ; 3-012

Breast Milk Feeding

and antenatal steroids: 9-007
and CMV infection: 2-010 ; 6-020; 10-024
and bacterial infection: 5-002
and hypothyroidism: 7-038
and iron supplementation: 4-046 ; 5-002
and Kangaroo Care: 2-047; 3-021
and Protein supplementation: 10-025
and ROP: 8-035
and SIDS risk: 10-013
and vitamin D supplementation: 4-015
feeding Hindmilk: 2-012
fortifiers: 5-002; 5-014; 7-039; 10-025
medications for production: 2-011
Premature babies: 2-013 ; 3-021; 5-014; 9-007; 10-025
Slow weight gain : 2-012; 10-025
Successful breast feeding: 2-040 ; 3-021; 9-009

Bronchopulmonary dysplasia,

and Nitric Oxide: 4-045 ; 6-017 ;
causes: 4-035 ; 6-026
definition: 4-047 ; 6-044
incidence: 2-001
oxygen treatment for: 5-006; 5-007; 11-027
postnatal steroids for: 2-053 ; 2-054 ; 2-055 ; 2-056; 5-041; 6-009; 6-010 ; 6-018; 8-016
prediction: 3-010 ; 3-041; 4-016
prophylaxis, complications: 1-002; 1-033, 2-001; 2-005; 2-006; 2-030 ; 2-036 ; 2-051; 5-033; 6-010; 11-027
room air challenges for: 4-047; 11-027

Bronze Baby Sundrome: 10-047

- C -

C reactive protein: 5-026 ; 6-042

C-section: 9-034 ; 10-005; 10-023; 10-035

Caffeine: 7-022 ; 7-034; 7-035; 8-017 ; 9-002

Candida infections:

and postnatal dexamethasone treatment: 2-029
and Severe retinopathy of prematurity: 2-029
and topical petrolatum ointment: 1-019
and Central catheter removal: 1-031
Empirical treatment: 4-043
fluconazole prophylaxis for: 2-002 ; 6-034; 7-047 ; 8-045
PCR assay for : 4-015
Risk factors: 7-047

Capnography: 2-046

Car Seat Testing: 2-035 ; 4-042; 8-012

Carbon Monoxide, end-tidal: 2-041; 2-042; 2-043; 2-044; 2-045; 3-036 ; 4-016

Cardiac Anomalies, screening for: 4-009; 9-023; 10-009; 10-028

Cardiac output: 3-020

Cardiac tamponade: 2-026; 3-032

Carnitine Supplementation: 6-023

cataracts: 3-026

Central Catheters: 1-031; 1-032

and Sepsis: 2-027; 11-010
complications: 3-032

Cerclage, cervical, complications: 3-008

Cerebral Palsy: 2-009 ; 2-053 ; 2-054 ; 2-055 ; 2-056; 5-034; 6-009; 6-010; 8-013; 8-014; 8-016; 8-024; 9-033

Cerebral Blood Flow: 5-039; 8-009; 9-008; 10-021

cervical cancer: 3-023 ; 4-003

chloral hydrate: 3-013

Cholestasis, evaluation : 2-031 ; 7-037

chronic lung disease,

and antenatal steroids: 2-006 ; 2-051
and Surfactant treatment: 1-004; 1-026; 1-036
and HFOV: 1-005; 1-008; 2-005; 2-014; 3-039 ; 3-040
and nitric oxide treatment: 1-014 ; 4-045 ; 6-017
and spironolactone treatment : 1-015
and Ureaplasma colonization: 3-049
definition: 4-047 ; 6-044
incidence: 2-001 ; 11-008
inhaled steroids for: 2-055
oxygen treatment for: 5-006 ; 5-007; 11-027
prediction: 3-010 ; 3-041; 6-026
postnatal steroids for: 2-053 ; 2-054 ; 2-055 ; 2-056; 5-041; 6-009; 6-010 ; 6-018; 8-016
prophylaxis, complications: 1-002; 1-033 ; 2-053 ; 2-054 ; 2-055 ; 2-056 ; 4-045; 6-009; 6-010; 11-008; 11-027
risk factors: 1-021; 1-026, 2-001 ; 3-041; 4-035; 6-026
room air challenges: 4-047; 11-008; 11-027
Sildenafil (Viagra) treatment: 10-016
Vitamin A supplementation : 5-033; 11-008

Circumcision:

and cervical cancer: 3-023; 8-019
and HPV infection: 3-023; 8-019
and Pain : 3-025
and STDs: 7-041; 8-019
Mogen Clamp vs Plastibell: 3-025

Click test for RDS: 1-023

Coagulase-negative Staphylococcus: 2-009

Computerized Physician Order Management: 11-023

Conscious sedation: 3-013

Coombs test: 3-036

Cord Blood : 4-020 ; 9-017

Cortisol, Hair: 8-033

CPAP:

for apnea of prematurity: 2-022
in the delivery room: 5-029 ; 6-037; 9-018
Nasal trauma from: 11-026
noise levels on: 9-019
predicting failures: With High frequency ventilation: 6-037
vs nasal SIMV after extubation: 2-023 ; 4-025
vs High Flow Nasal Cannula: 8-005
With High frequency ventilation: 5-022

CPT coding: 4-017

Cultures, Blood: 3-042 ; 4-015

Cycled Lighting: 3-022 ; 5-019

Cytokines

and periventricular leukomalacia: 2-052
and sepsis screening: 5-026
G-CSF : 2-003
GM-CSF: 2-004

Cytomegalovirus: 2-010 ; 6-020; 10-024

- D -

Dead space, pulmonary and acoustic output: 1-013

Delayed umbilical cord clamping : 1-024 ; 3-019 ; 4-038; 8-009

Desaturations:

and GE reflux: 3-001 ; 3-012
and supine positioning: 1-016
evaluation: 3-001 ; 3-002 ; 3-012

Developmental Care: 4-019 ; 5-019; 10-042

Dexamethasone:

and cerebral palsy: 2-053 ; 2-054 ; 2-055 ; 2-056; 6-009; 6-010
and fungal sepsis: 2-029
and small bowel perforation: 1-002; 1-033; 2-030 ; 2-036 ; 3-047
and retinopathy of prematurity: 2-029
antenatal: 7-018

DHA supplementation, maternal: 4-011

Diaphragmatic hernia: 1-011 ; 3-044 ; 4-039; 5-032; 10-014

dilated eye exams: 3-026

Diuretics for CLD : 1-015

DNase nebulizations: 2-032

Dopamine: 3-020; 5-039; 9-048

Dobutamine: 3-020

Down's Syndrome: 10-041

DRIFT treatment for hydrocephalus: 4-012; 8-018

Drug testing: 7-003; 11-025

Duct tape: 4-004

- E -

E. coli Infections: 1-001; 2-048; 3-035

Echocardiography

in PPHN: 2-019 ;
for UVC position : 4-008

ECMO need and nitric oxide treatment: 1-014

EEG in HIE: 1-027

Encephalopathy:

Hypothermia for: 1-027 ; 6-039c; 6-040; 10-027; 10-040; 10-048
Predicting: 5-005; 10-048

End of Life Decisions: 8-039; 10-029

End-tidal CO2 monitoring: 2-046 ; 3-036

Endotracheal intubation: 2-046 ; 6-019; 7-036

Enterovirus Infection: 8-043

Environmental Triggers: 10-007

Epidural anesthesia: 4-030

and fever: 1-003 ; 1-037 ; 4-044

Erb's Palsy, surgery for: 1-022

Erythromycin: 8-003

Erythropoietin: 3-015; 3-037 ; 4-040; 10-038

Esophageal pH monitoring: 3-011 ; 3-012

Esophagitis: 3-011

estimated gestational age and survival: 1-007; 1-025; 1-026; 6-011

extra-uterine growth retardation: 4-021

ELBW infants:

and advanced maternal age: 10-020
and skin care: 1-019; 1-041 ; 6-015
and Growth: 4-021 ; 4-026; 9-047
and Indomethacin prophylaxis: 1-042; 2-025
and phototherapy: 9-046
Ethical and Legal Issues: 7-029; 9-041
Neurodevelopmental outcomes: 1-020; 1-025; 3-009; 5-034; 6-011; 8-021
Outcomes to hospital discharge: 1-026, 2-001; 9-021
Oxygen requirement: 2-057 ; 5-006; 5-007

Epinephrine: 9-013

Ethicss: 10-029; 10-033

EXIT strategy : 6-033

- F -

Factor VIIa: 7-043

Family Centered Care: 11-014

feeding:

during blood transfusions: 11-024
post-discharge: 5-012
techniques: 2-028 ; 2-047 ; 3-017 ; 3-048 ; 4-010 ; 5-040 ; 6-022
tolerance: 2-034; 3-017; 4-002; 4-010; 5-040; 6-008 ; 6-022; 8-003; 8-034; 9-001; 9-039

fetal distress: 6-046

fever, maternal and neonatal outcome: 1-003 ; 1-037

Fish Oil: 7-026

fluconazole prophylaxis : 2-002; 6-034; 7-037; 8-025; 8-045

Folic acid:

antagonists: 1-038
supplementation: 3-028; 8-030

Free Radicals and PVL: 2-052

Fungal Sepsis:

and dexamethasone treatment: 2-029
and retinopathy of prematurity: 2-029 ; 9-010
Empirical treatment: 4-043
PCR assay for : 4-015
Prophylaxis: 6-034 ; 2-002; 7-037; 7-047; 8-025; 8-045
Risk Factors: 7-047

Furosamide and hearing loss: 4-007

- G -

Gallbladder stasis and continuous feeding: 2-028

Gastric Residuals: 3-017

Gastroesophageal reflux: 3-001; 3-011 ; 3-012; 5-011; 5-030 ; 6-041 ; 7-033 ; 9-001; 9-006; 10-015; 10-037

Gentamicin dosing: 5-003

Gestational Age terminology: 1-030

Ganulocyte Colony-Stimulating Factor: 2-003

Glucagon treatment: 2-039

Glucocorticoids, antenatal: 2-006 ; 2-051

Glucose: 5-013 ; 5-035

Glycerin enemas: 8-034

Growth, preterm babies: 3-022 ; 4-021 ; 4-022; 4-026

Granulocyte-Macrophage Colony-Stimulating Factor: 2-004

Gut Priming: 3-017 ; 4-010; 5-040

- H -

Head growth: 4-022

Heal Warming: 3-016

Hearing Loss :

and Medications: 4-007
Newborn screening: 7-016; 8-042

Hemoglobin, transcutaneous: 6-038

Hemolytic disease of the Newborn: 2-041; 2-042; 2-043; 2-044; 2-045; 3-036

Heparin in IV solutions: 5-001; 8-001

High Flow Nasal Cannula: 8-005

High frequency ventilation:

and cerebral palsy risk: 8-013
and chronic lung disease: 1-008; 2-005; 2-014 ; 3-039 ; 3-040
and intraventricular hemorrhage: 1-008; 2-014 ; ; 3-039 ; 3-040
early : 1-005; 2-014 ; 3-039 ; 3-040
exhaled CO2 monitoring during: 2-015
long term outcomes after: 1-006
low vs high frequency effects: 1-010
MAP optimization: 2-017 ; 9-020
partial ET tube occlusion during: 2-016
pressure-time waveforms: 2-017 ; 9-020
tidal volumes: 1-009
with nasal CPAP: 5-022

Hind Milk: 2-012

Hip dysplasia screening : 1-017

HIV: 5-027

human milk fortifier: 5-014 ; 7-039; 10-025

Humidified High Flow Nasal Cannula: 8-005

human papilloma virus: 3-023 ; 4-003

Hyaline Membrane disease:

Click test for: 1-023
HFOV for: 2-005; 2-014 ; 3-039 ; 3-040
Treatment: 6-016; 8-027

Hydrocephalus, treatment: 4-012 ; 8-018

Hydrocortisone:

treatment for hypertension: 2-021; 7-010
antenatal: 2-051
postnatal: 5-041; 6-009 ; 6-018; 6-025; 7-010; 8-016; 8-031

Hydrolyzed formulas: 4-002

Hyperbilirubinemia, direct: 2-031

Hyperglycemia: 7-044 ; 7-045

Hyperinsulinism: 7-015

Hyperkalemia, treatment: 1-034

Hypernatremia: 8-004

Hypertension

in premature babies: 2-021;
steroid treatment: 2-021

Hypoglycemia, neonatal: 1-043, 2-039 ; 4-038; 5-035; 7-015; 7-027; 10-010

Hyponatremia: 2-039

HYpoplastic Left Heart: 9-015

Hypotension: 5-039; 7-010 ; 9-003; 9-045; 9-048; 10-021; 10-032

Hypothermia

for HIE: 1-027 ; 3-060 ;6-039 ; 6-040; 10-027; 10-040; 10-048; 11-021
for NEC: 11-013
Prevention of: 6-003; 8-010

Hypothyroidism, screening: 3-024 ; 7-038

Hypotonia and maternal fever: 1-003

Hypoxic-ischemic encephalopathy: 1-027; 3-009; 3-060; 5-005; 5-035; 6-012; 6-039 ; 6-040; 10-018; 10-027 ; 11-021

Oxygen vs room air resuscitation: 2-024 ; 4-013

- I -

Iatrogenic injury in NICU: 10-012

ibuprofen for PDA : 1-018; 9-016; 10-001; 10-002

imaging, cranial: 4-018; 10-026

Immunizations: 4-032 ; 6-043; 7-004; 8-032; 9-036

indomethacin:

and carnitine supplementation: 6-023
and long-term outcome: 2-025
and necrotizing enterocolitis: 3-047 ; 4-027 ; 4-029
and small bowel perforation: 1-002; 1-033; 3-047; 4-027 ; 7-011
as IVH prophylaxis: 1-042; 2-025: 3-047
late vs early for PDA: 2-007; 2-025: 3-047 ; 4-029 ; 4-041; 8-002; 9-031
tocolysis: 6-021; 8-002
vs ibuprofen for PDA : 1-018; 3-047; 9-016

Infantile Myoclonus: 6-035

Inotropes: 3-020

Insulin: 5-013

Internet technologies in NICU: 1-039

intrapartum Antibiotic Prophylaxis: 1-001 ; 2-048 ; 4-044; 6-032

Intrauterine Growth Retartdaion: 7-022; 9-042

intraventricular hemorrhage: and anemia: 2-038
and cerebral blood flow: 5-036 ; 5-039; 8-008
and delayed cord clamping: 7-013
and high frequency ventilation: 1-008; 2-014 ; 3-039 ; 3-040
and hypercapnea: 7-020; 8-008
and indomethacin tocolysis: 6-021
and periventricular leukomalacia: 2-052; and surfactant treatment: 1-004
incidence: 2-001
prediction: 3-010; 8-008
prophylaxis: 1-042; 2-025 ; 3-033; 3-047 ; 4-045
screening: 4-018; treatment: 4-012 ; 8-018

Iron

supplementation: 1-028 ; 4-046 ; 7-005
and Periventricular leukomalacia: 2-052

Ischemia, tissue: 3-038

IV infiltrates: 3-038

- J -

Jaundice,

cholestatic: 2-031

Evaluation of: 2-041; 2-042; 2-043; 2-044; 2-045; 3-031; 3-036; 5-023; 5-024; 7-017; 9-024; 10-043

- K -

Kangaroo Mother Care: 2-047 ; 5-018

Kernicterus: 5-023 ; 5-024; 7-007; 7-017; 10-022; 10-043

- L -

Lactic acid : 3-048 ; 5-005

Late Preterm Infants: 10-017; 10-023

length of stay:

and early HFOV: 1-005
and Kangaroo Mother Care: 2-047
and Parent Education: 7-040

Leukemoid Reactions: 6-026

levels of NICU care: 3-057

lighting, reduced: 2-049 ; 3-022 ; 4-019

Liquid Ventilation: 6-007

Liver abscesses: 4-024

Locomotor Function: 3-009

Lumbar Punctures: 5-017

lung growth and development: 4-035

lung lavage: 4-033 ; 4-034

lung volume assessment : 1-011

- M -

Magnesium sulfate: 3-033 ; 8-011; 9-033

Mechanical ventilation:

and chronic lung disease: 1-021; 2-005; 2-014 ; 3-039 ; 3-040
and long-term outcomes: 6-024
and tidal volume monitoring: 1-035; 2-014

Meconium Aspiration Syndrome: 4-033 ; 4-034 ; 6-031

Meconium Ileus: 5-025

Meconium Staining: 7-008

Medication Errors: 11-023

Medications : 9-028

Meningitis : 5-017; 8-043

Methamphetamine: 7-042

Methicillin-resistant staph aureus: 7-032 ; 9-012

Milrinone: 9-045

Misplaced Umbilical Vein Catheters: 2-050; 3-032

Mogen Clamp for circumcision: 3-025

Monitoring Studies: 3-001 ; 3-002

Morphine: 5-037 ; 3-038

Mortality:

and early HFOV: 1-005; 2-005
and Kangaroo Care: 2-047
and hyperglycemia: 7-044
and hypothermia: 8-010
and neonatologist supply: 3-029; 3-030
and NICU beds: 3-029 ; 3-030
and Oxygen saturation target: 11-027
associated with PICC lines: 2-026
in extremely premature infants: 1-025 ; 2-001; 6-011
in Group B Strep sepsis: 1-036
prediction: 3-010

Motor development: 3-009

MRI :

and lung volume: 1-011
cranial: 11-020
for PVL : 5-034; 10-026
post-mortem: 10-034
without sedation: 5-008

Multidisciplinary teams: 11-017

Multiple pregnancies: 10-003

Multi-vitamin supplementation: 3-027

- N -

Naloxone: 4-030

Nasal cannula : 2-022 ; 8-005

Nasal SIMV : 2-023 ; 4-025 ; 8-047

Necrotizing enterocolitis: 3-028 ; 3-047 ; 4-010; 4-027 ; 4-029 ; 6-001; 6-042 ; 7-001; 7-021; 7-028; 7-044 ; 9-037 ; 10-011; 11-013; 11-024

Neonatal resuscitation- 8-026; 11-012

oxygen vs room air: 2-024 ; 6-045; 7-006

Neonatologists, manpower: 3-029 ; 3-030

Neonatology: Past, present and future: 2-018

Neural Tube defects: 8-030

Neurodevelopmental Outcomes

in ELBW infants: 1-020; 1-025; 2-025; 2-057; 3-009 ; 4-019; 5-036; 5-037; 3-038; 6-011; 6-024; 6-025; 8-031; 8-038; 9-002; 9-004; 9-040; 10-038; 10-042; 11-015

in near-term babies: 9-027; 10-038

Neurologic Optimality Score: 3-009

NICU, classification: 3-057

nitric oxide treatment : 1-014; 2-019 ; 4-045; 5-021 ; 6-017; 7-030 ; 7-031; 8-024; 8-040

Nitroglycerin ointment: 3-038

Nosocomial Infection: 1-041; 2-027; 6-029; 11-010

NSAIDs and PPHN: 2-008

Nutrition in VLBW infants: 5-031 ; 5-033; 6-023; 7-039

- O -

Omphalocele: 3-028

Omphalitis: 4-001

Osteopenia of prematurity: 9-035

Outcomes with reduced lighting: 2-049

Oxygen :

requirement in ELBW infants: 2-057 ; 3-043 ; 4-006; 5-006; 5-007; 10-036; 11-027
Saturation at birth: 7-024; 8-046; 10-036

- P -

Palivizumab (Synagis): 9-032

Pacifiers: 7-019

Pain response: 7-023 ; 9-029

Parent Education: 7-040

Patent Ductus Arteriosus

and BNP: 11-009
and Magnesium sulfate: 8-011
and hypotension: 9-048
diagnosis: 8-022; 9-038
ibuprofen treatment: 1-018 ; 3-047; 9-016; 10-001; 10-002; 11-016
inhibition of closure: 11-022
late vs early indomethacion rx: 2-007; 2-025 ; 3-047; 4-027 ; 4-029 ; 4-041; 9-031; 11-016
Prophylaxis with indomethacin: 1-042; 2-025 ; 3-047; 11-016
Risks: 9-005; 11-022

Perfluorocarbons: 6-007

perforation, small bowel: 1-002 ; 1-033 ; 2-030 ; 2-036; 3-047; 4-027 ; 7-011

Pericardial effusion: 2-026 ; 3-032 ; 8-020

Perinatal counseling: 6-027 ; 6-028; 9-041

periventricular leukomalacia:: and cerebral blood flow: 5-036
and indomethacin prophylaxis: 2-025; and nitric oxide: 4-045
and surfactant treatment: 1-004
Incidence in VLBW infants: 1-026 ; 5-034
Pathogenesis: 2-052
Prevention: 2-052
Screening: 4-018 ; 5-034; 10-026; 11-020

Persistant pulmonary hypertension :

Causes: 2-008 ; 7-009
Evaluation: 11-009 ; 11-011
treatment: 1-012; 1-014; 2-019; 2-020; 3-058; 5-021; 7-014; 8-024; 10-016
Transport: 11-011

Pertussis Immunization: 7-004

Phenobarbital and birth defects: 1-038

Phenytoin and birth defects: 1-038

Phototherapy: 9-046

Physical therapy: 9-035

PICC Lines:

and Sepsis: 2-027
Cobweb sign: 6-036
Complications of: 2-026 ; 3-032; 11-018

Plastibell for circumcision: 3-025

Platelet function: 10-002

Pneumonia, treatment for: 1-029

Point of care testing: 6-004

Positioning and GER: 5-030

Preauricular tags and Pits: 3-045; 9-044

Premature rupture of membranes: 3-003 ; 3-004 ; 3-005 ; 3-006; 3-007 ; 3-008 ; 3-018

Prenatal Consults: 11-019

Preterm Labor, prevention of : 4-005

Prebiotics: 9-030

Probiotics : 6-001 ; 9-026; 9-030

Prone Sleeping and SIDS: 1-040

Prostaglandin E1 : 10-008

Pulse oximety

alarm limits: 2-057
and cardiac anomalies: 4-009 ; 9-023; 9-043; 10-009
in the delivery room: 6-045; 8-046
interference: 10-047
fetal: 6-046

- Q -

(empty)

- R -

Race discrimination: 11-025

Readmission rates: 8-044

Red Reflex Examination: 3-026

Renal Ultrasound: 3-045

Renal function: 9-014

Residuals, gastric : 3-017

Respiratory Distress Syndrome:

Click test for: 1-023
HFOV for: 2-005; 2-014 ; 3-039 ; 3-040
Nitric Oxide for: 4-045
Treatment: 5-020 ; 6-016 ; 6-017; 8-027; 8-047

Respiratory Failure, term: 6-013

Respiratory Syncytial Virus infection: 8-044; 9-032

resuscitation - oxygen vs room air: 2-024 ; 4-013; 4-028; 7-006; 9-022; 9-025; 10-036
                    - teamwork: 11-012
                   - with CPAP in the delivery room : 5-029; 7-006; 9-018
                   - When to stop: 10-048

resuscitation need, and maternal fever: 1-003

retinoblastoma screening: 3-026

Retinopathy of Prematurity

and bilirubin levels : 4-023
and breast milk feedings: 8-035
and dexamethasone treatment: 2-029
and early HFOV : 1-005
and fungal sepsis: 2-029; 9-010
and hyperglycemia: 7-045
and oxygen saturation: 4-006 ; 5-006; 5-007; 11-027
and reduced lighting: 2-049
Incidence in ELBW infants: 1-026 ; 3-043 ; 6-030
Mediators : 3-059; 8-006
Prevention: 3-059; 8-006; 8-035; 11-027
Treatment: 6-005 ; 8-015

Rickets and Vitamin D supplementation: 4-015

Rupture of Membranes, Preterm, Premature: 3-003; 3-004 ; 3-005 ; 3-006 ; 3-007 ; 3-008 ; 3-018

Back to Top

- S -

Sacral dimple: 10-046

Sacral Ultrasound: 10-046

Seizures, and maternal fever: 1-003 ; 1-037

Sedation, procedural: 3-013

Seizures: 6-035

Sepsis, neonatal,

and 48 hour blood cultures: 3-042 ; 5-016
and Central catheters: 1-031; 1-032; 2-027; 11-010
and delayed cord clamping: 7-013
and hyperglycemia: 7-044
and skin care: 1-019; 1-041;
and surfactant treatment: 1-036
and thrombocytopenia: 10-039
cost of care: 5-028
Laboratory tests for: 5-016; 5-026; 8-023
organisms: 3-035
prevention: 3-034 ; 3-046; 3-056; 10-031; 11-010
Risk Factors: 1-001; 2-048; 5-016; 6-032
Treatment duration: 6-014 ; 7-002